Schizophrenia News and Research

Latest Schizophrenia News and Research

Study points to synergistic relationship between lead exposure and schizophrenia gene

Mice engineered with a human gene for schizophrenia and exposed to lead during early life exhibited behaviors and structural changes in their brains consistent with schizophrenia.

1 Jun 2013

New avatar system could provide quick and effective therapy for schizophrenia

An avatar system that enables people with schizophrenia to control the voice of their hallucinations is being developed by researchers at UCL with support from the Wellcome Trust.

31 May 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Omeros announces positive results from OMS824 Phase 1 clinical program

Omeros Corporation today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program.

31 May 2013

Research discovery may lead to development of new therapies for neurological disorders

For several years, the pharmaceutical industry has tried to develop drugs that target a specific neurotransmitter receptor in the brain, the NMDA receptor. This receptor is present on almost every neuron in the human brain and is involved in learning and memory. NMDA receptors also have been implicated in several neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

29 May 2013

Harmless genetic variations may team up to increase risk of schizophrenia, find researchers

Using a novel method of analyzing genetic variations in families, researchers at Johns Hopkins have found that individually harmless genetic variations affecting related biochemical processes may team up to increase the risk of schizophrenia.

29 May 2013

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Alkermes plc today presented positive results from a phase 1 study of ALKS 3831, a novel drug candidate for the treatment of schizophrenia, in an oral session at the 53rd Annual New Clinical Drug Evaluation Unit Meeting in Hollywood, Fla.

28 May 2013

Blinding and blinding assessment rarely documented in trial reports

A paper published in the current issue of P&P? tests the widely accepted assumption in drug trials: neither evaluators nor patients know whether the patient is getting drug or placebo (double blindness).

28 May 2013

Researchers are exploring how healthy people who hear voices can help schizophrenics

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen. Researchers from the Bergen fMRI Group at the University of Bergen (UiB) are working on how to help schizophrenics, who hear voices. The way they do this is by studying people who also hear voices, but who do not suffer from a mental illness.

27 May 2013

Calyx of Held: The largest synapse could shed light on neuropsychiatric disorders

Humans and most mammals can determine the spatial origin of sounds with remarkable acuity. We use this ability all the time -- crossing the street; locating an invisible ringing cell phone in a cluttered bedroom.

27 May 2013

Study finds differences in the brains of patients suffering from psychiatric diseases

Studying the networks of connections in the brains of people affected by schizophrenia, bipolar disease or depression has allowed Dr. Peter Williamson, from Western University, to gain a better understanding of the biological basis of these important diseases.

24 May 2013

Researchers reveal new insights about the process of axon amputation

As the human body fine-tunes its neurological wiring, nerve cells often must fix a faulty connection by amputating an axon - the "business end" of the neuron that sends electrical impulses to tissues or other neurons. It is a dance with death, however, because the molecular poison the neuron deploys to sever an axon could, if uncontained, kill the entire cell.

24 May 2013

Weekend reading: Mental illness stigma, health insurance mazes and female libido

Linneah sat at a desk at the Center for Sexual Medicine at Sheppard Pratt in the suburbs of Baltimore and filled out a questionnaire. She read briskly, making swift checks beside her selected answers, and when she was finished, she handed the pages across the desk to Martina Miller, who gave her a round of pills.

24 May 2013

FDA clears Omeros' OMS824 IND for treatment of Huntington's disease

Omeros Corporation today announced that its Investigational New Drug Application to evaluate OMS824 in Huntington's disease has been cleared by the U.S. Food and Drug Administration.

23 May 2013

NIH-funded study raises hope for recovery of some adult patients with brain disorder

Scientists have reversed behavioral and brain abnormalities in adult mice that resemble some features of schizophrenia by restoring normal expression to a suspect gene that is over-expressed in humans with the illness.

23 May 2013

Viewpoints: Sebelius' 'ethical line'; As tricky phase of health law approaches, concerns about exchanges opening on time

One of the biggest questions hanging over the health-care system is how many young Americans will sign up for coverage once the Affordable Care Act begins to phase in this October. If too few buy insurance on the markets that the government is creating, insurance companies would be stuck covering primarily the old and the sick. They would have to pay out more per customer.

21 May 2013

First alcoholic drink during puberty increases risk of alcohol problems

Research shows that the earlier the age at which youth take their first alcoholic drink, the greater the risk of developing alcohol problems. Thus, age at first drink (AFD) is generally considered a powerful predictor of progression to alcohol-related harm.

18 May 2013

BioLineRx signs ATM sales agency agreement with Stifel

BioLineRx Ltd., a biopharmaceutical development company, announced today that it has entered into an at-the-market sales agency agreement with Stifel.

18 May 2013

Thioridazine works by weakening staphylococcal cell wall, new study reveals

In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as staphylococci (Staphylococcus aureus).

18 May 2013

Weekend reading: Volunteers in the battle with heart disease; Psychiatry without medication; Owning your genes

Psychiatrists who take time with their patients are not the norm. It's not because others don't care. Rather the system rewards efficiency, not empathy.

17 May 2013

Schizophrenia News and Research

Latest Schizophrenia News and Research

Study points to synergistic relationship between lead exposure and schizophrenia gene

New avatar system could provide quick and effective therapy for schizophrenia

GLYX-13 drug induces antidepressant results without street drug side effects

Omeros announces positive results from OMS824 Phase 1 clinical program

Research discovery may lead to development of new therapies for neurological disorders

Harmless genetic variations may team up to increase risk of schizophrenia, find researchers

Alkermes reports positive results from phase 1 study of ALKS 3831 for treatment of schizophrenia

Blinding and blinding assessment rarely documented in trial reports

Researchers are exploring how healthy people who hear voices can help schizophrenics

Calyx of Held: The largest synapse could shed light on neuropsychiatric disorders

Study finds differences in the brains of patients suffering from psychiatric diseases

Researchers reveal new insights about the process of axon amputation

Weekend reading: Mental illness stigma, health insurance mazes and female libido

FDA clears Omeros' OMS824 IND for treatment of Huntington's disease

NIH-funded study raises hope for recovery of some adult patients with brain disorder

Viewpoints: Sebelius' 'ethical line'; As tricky phase of health law approaches, concerns about exchanges opening on time

First alcoholic drink during puberty increases risk of alcohol problems

BioLineRx signs ATM sales agency agreement with Stifel

Thioridazine works by weakening staphylococcal cell wall, new study reveals

Weekend reading: Volunteers in the battle with heart disease; Psychiatry without medication; Owning your genes

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Schizophrenia News and Research

Latest Schizophrenia News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in